Soligenix, Inc. announced that it has appointed Rasappa Arumugham, PhD, as its Vice President of Biopharmaceutical Development. Dr. Arumugham has over 25 years of diverse experience in biopharmaceutical research and development (R&D) in the areas of formulation research, analytical method development, quality control (QC), and manufacturing. He has a proven track record in development, scale-up, and technology transfer supporting commercialization of vaccines and biologics, including Prevnar(R), Tetramune(TM), HibTITER(R), Meningitec(R) Conjugate and meningitis B (bivalent rLP2086) Lipoprotein Subunit Vaccines.

Most recently, Dr. Arumugham served as the Head of Microbial Vaccines Analytics at Merck's Manufacturing Division.